68
Participants
Start Date
September 6, 2011
Primary Completion Date
April 11, 2016
Study Completion Date
April 11, 2016
Cisplatin
Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)
Gemcitabine
Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
ALT-801
Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
UPMC Cancer Center, Pittsburgh
St. Luke's Hospital and Health Network, Easton
Thomas Jefferson University Hospital, Philadelphia
Levine Cancer Institute, Charlotte
Emory University, Atlanta
UF Health Center at Orlando Health, Orlando
H. Lee Moffitt Cancer Center and Research Institute, Tampa
Martin Health System, Stuart
Karmanos Cancer Center, Detroit
University of Iowa Hospitals and Clinics, Iowa City
University of Minnesota, Minneapolis
Robert Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Washington University, St Louis
University of Kansas Cancer Center, Fairway
University of Oklahoma Health Science Center, Oklahoma City
The University of Arizona Cancer Center, Tucson
Lead Sponsor
National Cancer Institute (NCI)
NIH
Altor BioScience
INDUSTRY